PRME
Prime Medicine, Inc.
Next earnings Aug 5, 2026 · consensus $-0.26 EPS, $1.28M rev
Last earnings -8.7% on 2026-05-07
$3.43
▲ +7.86%$3.43▲ +65.70%
over 1Y
L $2.07EODHDH $6.67
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+7.9%
1W+7.9%
1M+3.9%
3M+1.5%
YTD-2.8%
1Y+65.7%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 19 analysts
Buy
Revenue grew 55.3% YoY; but unprofitable (net margin -4342.4%).
Prime Medicine, Inc. shows $4.63M in FY2025 revenue (+55.3% YoY), a -4342.4% net margin, and -166.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $2.98M | $4.63M |
| Gross profit | — | — | — | — | — |
| Operating income | -$84.5M | -$117M | -$205M | -$202M | -$208M |
| Net income | -$165M | -$122M | -$198M | -$196M | -$201M |
| Diluted EPS | -$14.19 | -$4.19 | -$2.18 | -$1.65 | -$1.35 |
| Net margin | — | — | — | -6566.6% | -4342.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$556M
EV / EBITDA—
EV / Sales120.1
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-32.5%
FCF yield-27.0%
Quality & risk
ROIC (est.)-136.2%
Free cash flow-$167M
Total debt—
Net cash$63.0M
Altman Z-Score-3.44 distress
Piotroski F-Score3/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+37.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-08open ↗8-KPeriod ending 2026-06-052026-06-08open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗ARSPeriod ending 2025-12-312026-04-23open ↗DEFA14AFiling2026-04-23open ↗
Frequently asked
- Is Prime Medicine, Inc. (PRME) a buy?
- PRME currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 55.3% YoY; but unprofitable (net margin -4342.4%).
- What is Prime Medicine, Inc.'s quality score?
- PRME scores 39.15686274509803/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001894562, latest 10-Q filed 2026-05-07) · EODHD · as of 6/22/2026, 10:54:16 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.